{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T16:43:13Z","timestamp":1784392993880,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1999,9,10]],"date-time":"1999-09-10T00:00:00Z","timestamp":936921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.1038\/sj.bjc.6690715","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:09:42Z","timestamp":1031249382000},"page":"457-462","source":"Crossref","is-referenced-by-count":73,"title":["A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck"],"prefix":"10.1038","volume":"81","author":[{"given":"C","family":"Couteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Chouaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Leyvraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Oulid-Aissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lebecq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Domenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Groult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Bordessoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Janot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M De","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[1999,9,10]]},"reference":[{"key":"BF6690715_CR1","first-page":"(abstract 208)","volume":"3","author":"M Aapro","year":"1992","unstructured":"Aapro, M, Zulian, G, Alberto, P, Bruno, R, Oulid-Aissa, D & Le Bail, N (1992). Phase I and pharmacokinetic study of RP56976 in a new ethanol free formulation. Ann Oncol 3: (abstract 208)","journal-title":"Ann Oncol"},{"key":"BF6690715_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/0959-8049(95)00124-2","volume":"5","author":"JP Armand","year":"1995","unstructured":"Armand, JP & Couteau, C (1995). Chemotherapy in head and neck treatment. Eur J Cancer 5: 819\u2013822.","journal-title":"Eur J Cancer"},{"key":"BF6690715_CR3","first-page":"4845","volume":"51","author":"MC Bissery","year":"1991","unstructured":"Bissery, MC, Guenard, D & Gueritte-Voegelein, F (1991). Experimental antitumor activity of taxotere, a taxol analogue. Cancer Res 51: 4845\u20134852.","journal-title":"Cancer Res"},{"key":"BF6690715_CR4","first-page":"523","volume":"53","author":"D Bissett","year":"1993","unstructured":"Bissett, D, Setanoians, A, Cassidy, J, Graham, MA, Chadwick, GA, Wilson, P, Auzannet, V, Le Bail, N, Kaye, SB & Kerr, DJ (1993). Phase I and pharmacokinetic study of taxotere administered as infusion. Cancer Res 53: 523\u2013527.","journal-title":"Cancer Res"},{"key":"BF6690715_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0304-3835(94)90196-1","volume":"81","author":"BJM Braakhuis","year":"1994","unstructured":"Braakhuis, BJM, Kagel, A & Welters, MJP (1994). The growth inhibiting effect of docetaxel (taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett 81: 151\u2013154.","journal-title":"Cancer Lett"},{"key":"BF6690715_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","volume":"1","author":"R Bruno","year":"1998","unstructured":"Bruno, R, Hille, D, Riva, A, Vivier, N, Bokkel Huinnink, W, van Oosterom, A, Kaye, S, Verweij, J, Fossella, F, Valero, V, Rigas, J, Seidman, A, Chevallier, B, Fumoleau, P, Burris, H, Ravdin, P & Sheiner, L (1998). Population pharmacokinetics\/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1: 187\u2013196.","journal-title":"J Clin Oncol"},{"key":"BF6690715_CR7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1200\/JCO.1993.11.5.950","volume":"11","author":"H Burris","year":"1993","unstructured":"Burris, H, Irvin, R, Kuhn, J, Kalter, S, Smith, L, Shaffer, D, Fields, S, Weiss, G, Eckart, J, Rodriguez, G, Rinaldi, D, Wall, J, Cook, G, Smith, S, Vreeland, F, Bayssas, M, Le Bail, N & Von Hoff, D (1993). Phase I clinical trial of taxotere administered as either a 2 hour or 6 hour intravenous infusion. J Clin Oncol 11: 950\u2013958.","journal-title":"J Clin Oncol"},{"key":"BF6690715_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/oxfordjournals.annonc.a058908","volume":"5","author":"G Catimel","year":"1994","unstructured":"Catimel, G, Verweij, J, Mattijssen, V, Hanauska, A, Piccart, M, Vanders, J, Franklin, H, Le Bail, N & Kaye, SB (1994a). Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533\u2013537.","journal-title":"Ann Oncol"},{"key":"BF6690715_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a058910","volume":"5","author":"G Catimel","year":"1994","unstructured":"Catimel, G, Vermorken, JB, Clavel, M, DeMulder, P, Judsen, I, Sessa, C, Piccart, M, Bruntsch, U, Verweij, J, Wanders, J, Franklin, H & Kaye, SB (1994b). A phase II study of gemcitabine in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 543\u2013547.","journal-title":"Ann Oncol"},{"key":"BF6690715_CR10","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1200\/JCO.1996.14.5.1672","volume":"14","author":"AI Dreyfuss","year":"1996","unstructured":"Dreyfuss, AI, Clark, JR, Norris, CM, Rossi, RM, Lucarini, JW, Busse, PM, Poulin, MD, Thornhil, L, Costello, R & Posner, MR (1996). Docetaxel an active new drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14: 1672\u20131678.","journal-title":"J Clin Oncol"},{"key":"BF6690715_CR11","first-page":"1037","volume":"53","author":"JM Extra","year":"1993","unstructured":"Extra, JM, Rousseau, F, Bruno, R, Clavel, M, le Bail, N & Marty, M (1993). Phase I and pharmacokinetic study of taxotere given as a short intravenous infusion. Cancer Res 53: 1037\u20131042.","journal-title":"Cancer Res"},{"key":"BF6690715_CR12","first-page":"181","volume":"15","author":"AA Forastiere","year":"1993","unstructured":"Forastiere, AA, Neuberg, D, Taylor, IVSG, De Conti, R & Adams, G (1993). Phase II evaluation of Taxol in advanced head and neck cancer: an eastern cooperative oncology group trial. J Natl Cancer Inst Monogr 15: 181\u2013183.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"BF6690715_CR13","first-page":"298 (abstr 859)","volume":"14","author":"H Fujii","year":"1955","unstructured":"Fujii, H, Sasaki, Y, Ebihara, S, Kida, Y, Ichikawa, G & Kaniyawa, S (1955). An early phase II study of docetaxel (taxotere) in patients with head and neck cancer. Proc Am Soc Clin Oncol 14: 298 (abstr 859)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690715_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/hed.2880150103","volume":"15","author":"D Gandia","year":"1993","unstructured":"Gandia, D, Wibault, P, Guillot, T, Bensmaine, A, Armand, JP, Marandas, P, Luboinski, B & Cvitkovic, E (1993). Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer. Head Neck 15: 8\u201315.","journal-title":"Head Neck"},{"key":"BF6690715_CR15","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/0959-8049(93)90095-W","volume":"9","author":"V Gebbia","year":"1993","unstructured":"Gebbia, V, Testa, A, Valenza, R, Zerillo, G, Restivo, S, Ingria, F, Cannata, G & Gebbia, N (1993). A pilot study of vinorelbine on a weekly schedule in recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29A 9: 1358\u20131359.","journal-title":"Eur J Cancer 29A"},{"key":"BF6690715_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/0959-8049(96)00002-0","volume":"5","author":"V Gebbia","year":"1996","unstructured":"Gebbia, V, Testa, A, Cannata, G & Gebbia, N (1996). Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 5: 901\u2013902.","journal-title":"Eur J Cancer"},{"key":"BF6690715_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3322\/canjclin.48.1.6","volume":"48","author":"SH Landis","year":"1998","unstructured":"Landis, SH, Murray, T, Bolden, S & Wingo, PH (1998). Cancer statistics, 1998. Cancer J Clin 48: 6\u201329.","journal-title":"Cancer J Clin"},{"key":"BF6690715_CR18","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/jnci\/84.23.1781","volume":"84","author":"R Pazdur","year":"1992","unstructured":"Pazdur, R, Newman, RA & Newman, BM (1992). Phase I trial of Taxotere: five days schedule. J Natl Cancer Inst 84: 1781\u20131788.","journal-title":"J Natl Cancer Inst"},{"key":"BF6690715_CR19","first-page":"115 (abstract 1","volume":"14","author":"P Ravdin","year":"1996","unstructured":"Ravdin, P, Valero, V, Nabholtz, JM, Hortobagyi, G, Oulid-Aissa, D, Riva, A, Houver, C & Bellet, R (1996). Efficacy of 5 day corticosteroid premedication in ameliorating taxotere induced fluid retention. Proc Am Soc Clin Oncol 14: 115 (abstract 124)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690715_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1288\/00005537-199105000-00009","volume":"101","author":"G Recondo","year":"1991","unstructured":"Recondo, G, Armand, JP, Tellez-Bernal, E, Domenge, C, Belehradek, M, De Vathaire, F, Wibault, P, Richard, JM & Cvitkovic, E (1991). Recurrent and\/or metastatic head and neck squamous cell carcinoma: a clinical, univariate, and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 101: 494\u2013501.","journal-title":"Laryngoscope"},{"key":"BF6690715_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0006-291X(05)81474-3","volume":"187","author":"JF Riou","year":"1992","unstructured":"Riou, JF, Naudin, A & Lavelle, F (1992). Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187: 164\u2013170.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6690715_CR22","first-page":"281 (abstract 9","volume":"13","author":"F Robert","year":"1994","unstructured":"Robert, F, Wheeler, RH, Molthrop, DC, Greene, P & Chen, S (1994). Phase II study of topotecan in advanced head and neck cancer, identification of an active new agent. Proc Am Soc Clin Oncol 13: 281 (abstract 905)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690715_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/oxfordjournals.annonc.a058258","volume":"3","author":"JH Schornagel","year":"1992","unstructured":"Schornagel, JH, Verweij, J, De Mulder, PH, Cognetti, F, Vermorken, JP, Cappeleare, Armand, JP, Wildiers, J, Clavel, M & Kirkpatrick, A et al (1992). Phase II trial of 10 ethyl 10 deaza aminopterin, a novel antifolate, in patients with advanced and\/or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 3: 223\u2013226.","journal-title":"Ann Oncol"},{"key":"BF6690715_CR24","first-page":"41","volume":"22","author":"RE Smith","year":"1995","unstructured":"Smith, RE, Thornton, DE & Allen, J (1995). A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 22: 41\u201346.","journal-title":"Semin Oncol"},{"key":"BF6690715_CR25","first-page":"479 (abstract 1","volume":"14","author":"Y Tanigawara","year":"1996","unstructured":"Tanigawara, Y, Sasaki, Y, Otsu, T, Fujii, H, Kashiwura, M, Sasaki, T, Okuamura, K & Taguchi, T (1996). Population pharmacokinetics of docetaxel in Japanese patients. Proc Am Soc Clin Oncol 14: 479 (abstract 1518)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6690715_CR26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1200\/JCO.1994.12.7.1458","volume":"12","author":"E Tomiak","year":"1994","unstructured":"Tomiak, E, Piccart, MJ, Kerger, J, Lips, S, Awada, A, De Valeriola, D, Ravoet, C, Lossignol, D, Sculier, JP, Auzannet, V, Le Bail, N, Bayssas, M & Kastersky, J (1994). Phase I study of docetaxel administered as 1 hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458\u20131467.","journal-title":"J Clin Oncol"},{"key":"BF6690715_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00001813-199507004-00004","volume":"6","author":"J Verweij","year":"1995","unstructured":"Verweij, J (1995). Docetaxel, an interesting new drug for the treatment of head and neck cancer and soft tissue sarcomas. Anti Cancer Drugs 6: 19\u201324.","journal-title":"Anti Cancer Drugs"},{"key":"BF6690715_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0889-8588(18)30414-3","volume":"5","author":"EE Vokes","year":"1991","unstructured":"Vokes, EE, Awan, AM & Weichselbaum, RR (1991). Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol\/Oncol Clin N Am 5: 753\u2013767.","journal-title":"Hematol\/Oncol Clin N Am"},{"key":"BF6690715_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1056\/NEJM199301213280306","volume":"328","author":"EE Vokes","year":"1993","unstructured":"Vokes, EE, Weichselbaum, PP, Lippman, SM & Hong, WK (1993). Head and neck cancer. N Engl J Med 328: 184\u2013194.","journal-title":"N Engl J Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6690715.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690715","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690715.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:56:02Z","timestamp":1684414562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6690715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9,10]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["BF6690715"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6690715","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,9,10]]}}}